Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNAI3 | P08754 | 1/20 | 0.38 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.38 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.38 |
| ▸ | CACNA1I | Q9P0X4 | 9/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 8/20 | 0.36 |
| ▸ | PRMT6 | Q96LA8 | 3/20 | 0.35 |
| ▸ | CARM1 | Q86X55 | 2/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | PIM1 | P11309 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21214167 | 0.86 | GNAI3 (0.51) | GNAI3GNAO1GNAI1CACNA1IKCNH2 | |
| SCHEMBL10246565 | 0.82 | GNAI3 (0.38) | GNAI3GNAO1GNAI1CACNA1IKCNH2 | |
| SCHEMBL23919190 | 0.82 | CACNA1I (0.49) | GNAI3GNAO1GNAI1CACNA1IKCNH2 | |
| SCHEMBL24170969 | 0.81 | PRMT6 (0.35) | GNAI3GNAO1GNAI1KCNH2PRMT6 | |
| SCHEMBL14614920 | 0.81 | GNAO1 (0.47) | GNAI3GNAO1GNAI1KCNH2 | |
| SCHEMBL10245112 | 0.79 | EPHX1 (0.41) | GNAI3GNAO1GNAI1CACNA1IKCNH2 | |
| SCHEMBL4569282 | 0.79 | NCF1 (0.46) | GNAI3GNAO1GNAI1 | |
| SCHEMBL17010887 | 0.79 | KDM1A (0.35) | CACNA1IKCNH2CACNA1H | |
| SCHEMBL19958952 | 0.78 | KCNH2 (0.52) | GNAI3GNAO1GNAI1CACNA1IKCNH2 | |
| SCHEMBL16745494 | 0.78 | ACHE (0.41) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130065883-A1 | Triazolo [4, 5- B] Pyridin Derivatives | Centro Nacional de Investigaceiones Oncologicas (CNIO) (ES) | 2013-03-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130065883-A1 | Triazolo [4, 5- B] Pyridin Derivatives | PIM1, PIM3, PIM2 | GNAI3 3323/4885GNAO1 4147/4885GNAI1 3630/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.